We found that the S100A12 plasma levels were higher in COVID-19 patients categorized as severe compared with mild/moderate, and compared with those in convalescence, and with healthy donors, but comparable with the levels in patients with community acquired pneumonia (Figure 3B). Here, S100A12 is linked to COVID-19.